Samia Joseph Khoury

The Comparative Effectiveness of Rituximab and Ocrelizumab in Relapsing-Remitting Multiple Sclerosis: A Real-World Study

Bassem Yamout, Raed Al-Roughani, Samar Farouk Ahmed, Akram Al-Mahdawi et autres

Multiple sclerosis outcomes after cancer diagnosis in people with recorded chemotherapy exposure: A real-world MSBase study

Cassie Nesbitt, Paul Sanfilippo, Chao Zhu, Serkan Ozakbas et autres

Background and objective: As more people with multiple sclerosis (MS) survive cancer, questions about MS management after cancer are increasingly relevant. This study aimed to describe post-cancer treatment patterns and MS outcomes in people with recorded chemotherapy exposure. Methods: Using MSBase, we …

au, tr, ca, it, cz, hr, kw, be, lb, nl (code pays fourni par la source)

Causal effects of multiple sclerosis therapies in left-truncated registry data

Dagmawi Chilot, Ibrahima Diouf, Serkan Özakbaş, Dana Horáková et autres

BACKGROUND: Left-truncation is an unrecorded interval between multiple sclerosis (MS) onset and initial data in observational studies. This delay may bias estimates of disease-modifying therapy (DMT) effectiveness, especially when determined by patient or disease characteristics. OBJECTIVES: To examine whether causal effect estimates …

au, tr, cz, it, es, kw, ca, lb, sk, ir, us, nl, be, Tunisie, hr, om, sa, hu, co, Égypte, ie, ee, gb, ro (code pays fourni par la source)

Tracking Eosinophilia in Multiple Sclerosis:Insights from Different Disease-Modifying Therapies

Aya S. Yatim, Fady G. Mikhael, ward harb, Mostafa Hijazi et autres

Upper Cervical Cord Area as a Biomarker of Conversion to Secondary Progressive Multiple Sclerosis

Nabil K. El Ayoubi, Sola Al Ghazal, Salem Hannoun, Medhat A. Siddik et autres

OBJECTIVE: This study assessed whether upper cervical cord area (UCCA) measured on routine brain MRI can serve as a biomarker of conversion to SPMS. METHODS: This is a single-center retrospective cohort study of RRMS patients with cross-sectional and longitudinal analyses of clinical …

lb, us (code pays fourni par la source)

Predicting disease progression in multiple sclerosis with clinically accessible information and technology

Tom A. Fuchs, Menno M. Schoonheim, Eva M. M. Strijbis, Julia R. Jelgerhuis et autres

BACKGROUND: Predicting disease progression at the individual level is essential for personalized medicine. We previously developed machine-learning tools to estimate 5-year progression risk in people with multiple sclerosis (PwMS). Such models should account for disease-modifying therapy (DMT) and objective outcome definitions. METHODS: …

nl, cz, us, tr, ca, kw, it, au, lb, be, pt, ch, es, gb, ir, om, ro, sa, hu, co, hr, in, gr, dk (code pays fourni par la source)

Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort Study

Izanne Roos, Sifat Sharmin, Serkan Ozakbas, Raed Alroughani et autres

BACKGROUND AND OBJECTIVES: Patients aged ≥ 35 years at multiple sclerosis (MS) symptom onset with an Expanded Disability Status Scale (EDSS) score ≥ 3 within the first year are at highest risk of developing aggressive MS (EDSS ≥ 6 within 10 years). …

au, tr, kw, es, ca, lb, it, nl, pt, be, Tunisie, om, ir, fr, mq, us (code pays fourni par la source)

Treatment escalation after clinically silent MRI lesions in relapsing-remitting multiple sclerosis

Cyrus Daruwalla, Courtney Kremler, Francesco Patti, Serkan Özakbaş et autres

Abstract Clinically silent MRI lesions occur frequently in people with relapsing-remitting multiple sclerosis (RRMS) despite disease modifying therapy (DMT). Guidelines only recommend DMT escalation after multiple silent lesions, and adherence is variable. We explored outcomes and the effect of treatment escalation following …

gb, pt, it, tr, au, lb, cz, hr, es, kw, be, ca, jp, nl, us, co, om, Tunisie, hu, ie, ee, ch (code pays fourni par la source)

Impact of Age at Onset on Relapse and Disability in AQP4-IgG Neuromyelitis Optica Spectrum Disorder

Pakeeran Siriratnam, Vilija G. Jokubaitis, Anneke Van Der Walt, Paul Gerard Sanfilippo et autres

BACKGROUND AND OBJECTIVES: Previous studies have reported inconsistent findings regarding the impact of age at onset on relapse risk in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4-IgG NMOSD), although older disease onset has been linked to more rapid disability accrual. This is …

gb, au, ir, tr, om, be, es, it, kw, mx, hr, lb, hu, in, si, cz (code pays fourni par la source)

The real-world effectiveness and safety of off-label rituximab in a large cohort of Middle Eastern multiple sclerosis patients

Ghida Ismail, Maya M Zeineddine, Raed Al-Roughani, Samar Farouk Ahmed et autres

Rituximab (RTX) is increasingly used off-label for the treatment of multiple sclerosis (MS), yet real-world evidence from Middle Eastern populations remains limited. This multicenter, retrospective observational study evaluated the effectiveness and safety of RTX using data from the MENACTRIMS registry across seven …

fr, lb, kw, iq, ae, om, Tunisie, sa, jo (code pays fourni par la source)

Comparative effectiveness of anti-CD20 therapies and S1P receptor modulators in late-onset multiple sclerosis: real-world evidence from the MSBase registry

Andrea Surcinelli, Tomáš Kalinčík, Izanne Roos, Emanuele D’Amico et autres

Background: Late-onset multiple sclerosis (LOMS), defined by symptom onset after age 50, is increasingly recognised as a distinct clinical entity. Evidence comparing disease-modifying therapies (DMTs) in this subgroup remains limited. Objectives: To compare clinical outcomes of anti-CD20 monoclonal antibodies and sphingosine-1-phosphate receptor …

it, au, tr, us, cz, nl, es, ca, lb, ir, kw, ch, si (code pays fourni par la source)

Effect of late-onset on multiple sclerosis phenotype and outcome: evidence from a multi-national registry

Amira Souissi, Francesco Patti, Tim D. Spelman, Clara Chisari et autres

Tunisie, it, se, au, ir, be, kw, lb, us, cz, Ouganda, ch, tr, co, es, ca, hr, nl, gb, ie, pt, in, dk, ro, ee, om, gr, ae, sa, hu, mx, mt (code pays fourni par la source)